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RESEARCH ARTICLE Open Access
Crossing barriers: a multidisciplinary
approach to children and adults with
young-onset movement disorders
Martje E. van Egmond1,2*† , Hendriekje Eggink1†, Anouk Kuiper1, Deborah A. Sival3,
Corien C. Verschuuren-Bemelmans4, Marina A. J. Tijssen1 and Tom J. de Koning1,3,4
Abstract
Background: Diagnosis of less common young-onset movement disorders is often challenging, requiring a broad
spectrum of skills of clinicians regarding phenotyping, normal and abnormal development and the wide range of
possible acquired and genetic etiologies. This complexity often leads to considerable diagnostic delays, paralleled
by uncertainty for patients and their families. Therefore, we hypothesized that these patients might benefit from a
multidisciplinary approach. We report on the first 100 young-onset movement disorders patients who visited our
multidisciplinary outpatient clinic.
Methods: Clinical data were obtained from the medical records of patients with disease-onset before age 18 years.
We investigated whether the multidisciplinary team, consisting of a movement disorder specialist, pediatric neurologist,
pediatrician for inborn errors of metabolism and clinical geneticist, revised the movement disorder classification,
etiological diagnosis, and/or treatment.
Results: The 100 referred patients (56 males) had a mean age of 12.5 ± 6.3 years and mean disease duration of 9.2 ± 6.
3 years. Movement disorder classification was revised in 58/100 patients. Particularly dystonia and myoclonus were
recognized frequently and supported by neurophysiological testing in 24/29 patients. Etiological diagnoses were made
in 24/71 (34%) formerly undiagnosed patients, predominantly in the genetic domain. Treatment strategy was adjusted
in 60 patients, of whom 43 (72%) reported a subjective positive effect.
Conclusions: This exploratory study demonstrates that a dedicated tertiary multidisciplinary approach to complex
young-onset movement disorders may facilitate phenotyping and improve recognition of rare disorders, with a high
diagnostic yield and minimal diagnostic delay. Future studies are needed to investigate the cost-benefit ratio of a
multidisciplinary approach in comparison to regular subspecialty care.
Keywords: Multidisciplinary, Young-onset movement disorders, Diagnosis, Dystonia, Myoclonus, Clinical phenotyping
Background
Young-onset movement disorders (YMDs) is a relatively
new field in neurology, comprising clinical neurological
syndromes presenting with involuntary movements mani-
festing before the age of 18. As with movement disorders
(MDs) in adults, YMDs are subdivided into hyperkinetic
movements (dystonia, myoclonus, chorea, ballism, tremor
and tics), hypokinetic (parkinsonism) movements, and
ataxia [1–5]. Recognition of common YMDs, such as tics
and stereotypies, is usually straightforward for most clini-
cians. However, diagnosis of less common and more com-
plex YMDs, such as disorders presenting primarily with
myoclonus or dystonia, is often difficult, both for pediatric
and adult neurologists [1, 6, 7].
The recognition and classification of YMDs present
some unique challenges. Firstly, YMDs are often embed-
ded in a complex clinical phenotype. For example, the
occurrence of mixed MDs (more than one MD present)
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or co-existence of a variety of symptoms such as psycho-
motor retardation or behavioral abnormalities are com-
monly seen [5, 8, 9]. Secondly, in young children the
developing nervous system may produce a variety of
motor patterns that would be labeled as pathologic in
older children and adults, but are simply a manifestation
of brain immaturity in younger patients [1]. For in-
stance, chorea is a normal feature in healthy infants and
toddlers, and (subtle) signs of overflow dystonia and
ataxia are found in healthy children up till the age of
12 years or even older [10, 11]. Finally, YMDs can be
caused by a broad spectrum of both acquired and gen-
etic disorders, including infections, auto-antibody and
auto-immune disorders, as well as rare metabolic disor-
ders and other inherited defects [7, 12–14].
The complexity of the diagnosis and management of
YMDs is becoming increasing clear, which has resulted
in a growing number of specialized pediatric neurolo-
gists. Despite this development, the diagnostic process in
complex YMDs often remains challenging, a burden for
patients and their families, and costly for our health care
system as patients often remain undiagnosed for many
years [1, 6, 7, 14, 15]. This has been reflected in a recent
study in a tertiary referral center that showed a mean
delay of diagnosis of 11.1 ± 12,5 years in a cohort of 260
patients with non-tic YMDs [7].
In other heterogeneous or rare diseases in children
such as epilepsy or neuromuscular disorders, a beneficial
effect of a multidisciplinary approach has been reported.
[16–20] We hypothesized that such an approach might
be a possibility to tackle the complexity of children and
young adults with MDs. A multidisciplinary team may
enable to overcome the three difficulties experienced in
this patient group: a complex clinical phenotype (move-
ment disorder specialist), the variety of motor patterns
produced by the developing brain (pediatric neurologist),
and a broad spectrum of both acquired and genetic dis-
orders (pediatrician for inborn errors of metabolism and
a clinical geneticist).
In this exploratory study, we report on the first 100
patients with YMDs who visited our multidisciplinary
outpatient clinic. Our aim was to share our experience
of a new multidisciplinary approach in terms of changes
in MD classification, diagnostic yield and targeted treat-
ment strategies.
Methods
Design and setting of the study
In this retrospective, single center, observational study
we evaluated the first 100 patients who visited our
multidisciplinary outpatient clinic for YMDs. It was situ-
ated in a tertiary referral center, the University Medical
Center Groningen, in the Netherlands. The study was
performed according to the ethical standards and regula-
tions of our institute.
Patients
All patients had a confirmed or suspected MD with an
onset before the age of 18 years and were referred for an
expert opinion regarding MD classification, etiology or
treatment of involuntary movements (Table 1).
Multidisciplinary outpatient clinic
The clinic was initiated in 2012 with a team consisting
of an adult neurologist specialized in MDs (MT), a
pediatric neurologist specialized in developmental neur-
ology and YMDs especially ataxia (DS), a pediatrician
specialized in metabolic diseases (TK) and a clinical
neuro-geneticist (CV). In addition, clinical fellows in
movement disorders and residents attend the clinic to
gain skills and knowledge from the different medical
specialties involved as part of their clinical training.
The pediatrician for inborn errors of metabolism re-
ceived the referrals as the coordinating medical special-
ist, which were subsequently discussed within the team.
Prior to the consultation, referral letters and medical re-
ports containing previous diagnostic and treatment
strategies were read carefully by the clinical fellow, who
sent a summary to all team members.
During the consultation, patients were seen by all team
members at once. In a separate meeting, the team mem-
bers reviewed the video images, discussed the movement
disorder classification and the results of the additional
investigations, and developed joint diagnostic and thera-
peutic recommendations. In all cases the team members
reached consensus. The main diagnostic steps were
laboratory investigations, (neuro-)imaging, clinical
neurophysiology or genetic testing. The key therapeutic
options comprised pharmacological treatment, botu-
linum toxin injections, paramedical interventions (e.g.
physiotherapy, occupational therapy, speech therapy),
ketogenic diet, and deep brain stimulation.
The primary purpose of the multidisciplinary team
was not to take over the clinical care provided by the re-
ferring medical specialist, but preferably to see a patient
once and provide an all-in-one expert opinion. The pres-
ence of the clinical geneticist enabled direct genetic
counseling in case genetic testing was considered.
Results of additional investigations and genetic diagnos-
tics were shared with the patient or caregivers by one of
the team members via a follow-up consult or, if pre-
ferred by the family, by a telephone consultation. The
team aimed to leave further management and follow-up
to the referring specialist, but in case of unresolved is-
sues patients were welcome to return to the multidiscip-
linary outpatient clinic.
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Data collection
We evaluated the first 100 patients who visited our
multidisciplinary clinic for YMDs between June 2012
and May 2014. Medical records were reviewed for pa-
tient characteristics and previous phenotypical classifica-
tions. The severity of the YMDs present was assessed by
the team members using the global clinical impression
scale of severity (GCI-S). This commonly used 7-point
scale enables a clinician to rate the extent movement dis-
orders with no movement disorder (1), slight (2), mild (3),
moderate (4), marked (5), severe (6), and among the most
severest (7) [21]. We compared the classification of the
most prominent MD and etiological diagnosis before and
after assessment by the multidisciplinary team. In
addition, we studied the treatment strategies and whether
the patients or their caregivers reported any positive ef-
fects of therapies 3–6 months after initiation. Since many
patients were not under our primary care, and/or living at
a distance from our center, we performed follow-up using
a semi-structured interview during a telephone consult-
ation. Patients and/or caregivers were asked (1) whether
they experienced benefit with regard to motor symptoms,
(2) since when they experienced this, (3) extent of im-
provement (none/slight/moderate/good), and (4) if any
adverse effects were present.
Results
Patient characteristics
A total of 56 male and 44 female patients visited the
multidisciplinary clinic (Table 1). Patients had a mean
age of 12.5 years (SD 6.3) and a mean duration of symp-
toms of 9.2 years (SD 6.3). Referring specialists were pre-
dominantly pediatric neurologists, pediatricians and
rehabilitation doctors with questions concerning the MD
classification, etiology or treatment options. We had 36
patients referred with an unclassified MD, documented
as dyskinesias, trembling, involuntary movements, or
restlessness. A confirmed etiological diagnosis (17 inher-
ited, 12 acquired) already explained the phenotype of 29
patients upon referral.
Movement disorder classification
Mean severity of the MDs present was 4.3 ± 1.7 on the
global clinical impression scale (range 1–7), correspond-
ing with a moderate to marked MD severity. The multi-
disciplinary team revised the initial classification in 58/
100 patients (Table 2). These revisions reduced the num-
ber of patients with an unclassified MD from 36 down
to 4. Compared to the referring clinicians, the team
more frequently classified the patients’ involuntary
movements as dystonia (from 32 to 41) and myoclonus
(from 11 to 31). The number of ataxic and tremor pa-
tients dropped (from 9 to 1 and 6 to 1, respectively),
Table 1 Baseline characteristics
Patient characteristics
Sex (male/female) 56/44
Age (years)a 12.5 ± 6.3; 1–33
Age at symptom-onset (years)a 3.3 ± 4.6; 0–18
Duration of symptoms (years)a 9.2 ± 6.3; 1–32
Referral questions














Coffin Lowry syndrome 1
Glutaric aciduria type 1 2
GLI2 mutation 1
GOSR2 mutation 1
GTPCH deficiency (DYT5) 1
Proprionacidemia 1
SCN1A mutation 2




(NFIX and CACNA1A gene)
1
Partial deletion chromosome 7q (SCGE gene) 1





aAge in years ± standard deviation; range
bChorea, tics, tremor, parkinsonism and if no MD was present
Abbreviations: ARX, Aristaless related homeobox; GOSR2, Golgi SNAP receptor
complex member 2; GTPCH, Guanosine Triphosphate Cyclohydrolase; SCN1A,
sodium channel voltage gated type I alpha subunit; TITF1, Thyroid transcription
factor-1; NFIX, nuclear factor I/X; CACNA1A, calcium channel voltage-dependent,
P/Q type, alpha 1A subunit; SCGE, epsilon-sarcoglycan
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whereas the number of patients with chorea increased
(from 4 to 6). The multidisciplinary team observed no
MDs in eleven patients (e.g. the movements were related
to agitation or caused by behavioral abnormalities). Sim-
ultaneous non-invasive surface electroencephalography/
electromyography (EEG/EMG) was performed in 29 pre-
dominantly myoclonic patients and this confirmed or
supported the MD classification observed by the team in
24/29 patients. In the remaining five cases, EEG/EMG
was not conclusive due to an absence of symptoms dur-
ing registration (n = 3) or the patient being unable to
comply with the registration protocol (n = 2).
Associated neurological and non-neurological features
Only 26/100 patients presented with a (mixed) MD
without associated features, whereas the majority of
patients also had additional neurological symptoms
(n = 35), non-neurological symptoms (n = 9) or both
(n = 30). The most important additional features were
intellectual disability, epilepsy, spasticity, skin abnormal-
ities, deafness, dysmorphias, and skeletal and growth
abnormalities.
Etiological diagnosis
At presentation, 29/100 patients had a confirmed genetic
or acquired cause explaining their phenotype (Table 1).
The multidisciplinary team established a diagnosis in 24
additional patients (Table 3), particularly in the genetic
domain, where the number of diagnoses more than dou-
bled from 17 to 37. Monogenetic etiologies were found
using single-gene testing in nine cases, by targeted rese-
quencing in three cases and using whole exome sequen-
cing in five cases. Biochemical testing led to a diagnosis
of non-ketotic hyperglycinemia in one case in which
confirmation of the molecular defect is still pending.
Among the acquired causes, oral contraceptive-
induced chorea was diagnosed in one patient and three
patients turned out to have functional MDs. Despite an
increase in confirmed etiological diagnoses from 29 to
53, we still had 35 patients categorized with a suspected
genetic diagnosis (defined as strong suspicion of a gen-
etic cause based on a severe clinical phenotype, early on-
set, family history, and absence of any of the known
acquired causes). In these cases, multiple genetic tests,
including whole exome sequencing, have not yet
Table 2 Overview of classification of most prominent MD before and after visiting the multidisciplinary outpatient clinic
Observed MD classification by the multidisciplinary team
Dystonia Myoclonusa Ataxia Otherb Unclassified Total
Referral MD classification Dystonia 26 1 0 4 1 32
Myoclonusa 0 10 0 1 0 11
Ataxia 0 8 0 1 0 9
Otherb 2 5 0 5 0 12
Unclassified 13 7 1 12 3 36
Total 41 31 1 23 4 100
aIsolated myoclonus, myoclonus ataxia and myoclonus dystonia
bComprises chorea, tics, tremor, parkinsonism and if no MD was present




















Gilles de la Tourette 1




Abbreviations: ACTB, beta-actin; CTNNB1, catenin (cadherin-associated protein)
beta 1; GLRA1, glycine receptor alpha 1; GOSR2, Golgi SNAP receptor complex
member 2; HSD17B10, 17beta-hydroxysteroid dehydrogenase type 10; MECP2,
methyl CpG binding protein 2; OFD-1, oral-facial-digital syndrome 1; OTC, ornithine
carbamoyltransferase; PRRT2, proline-rich transmembrane protein 2; SPTBN2,
spectrin beta non-erythrocytic 2; TH, tyrosine hydroxylase; TITF1, thyroid
transcription factor-1; HSD17B10 or 2-methyl-3-hydroxybytyryl-CoA
dehydrogenase deficiency.
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revealed a causative molecular defect. For 21 of these 35
patients we are awaiting elucidation of the causal muta-
tion in a research setting, the other 14 patients (or their
caregivers) decided not to participate in this research.
Treatment strategies
More than half of the 100 patients (61%) had not been
given any specific treatment for their MD before visiting
our clinic. The multidisciplinary team initiated or chan-
ged the treatment strategy in 60/100 of the patients.
Table 4 gives an overview of changes in the treatment
strategy, categorized by MD type. In 30/60 cases (50%),
the new treatment strategy was based on the revised
MD classification. In the other 30 patients the team ini-
tiated or adjusted the treatment strategy, despite an un-
changed MD classification: for example symptomatic
treatment with trihexyphenidyl in dystonic cerebral
palsy. We advised six patients to stop their medication,
which led to unchanged clinical symptoms in two pa-
tients and an improvement of symptoms in three others.
An example of the latter was advice to stop taking oral
contraceptives, which led to an almost complete dis-
appearance of adolescent-onset chorea. In the group of
60 patients who had new or adjusted treatment, 72% of
them or their caregivers reported a positive effect ther-
apy after 3–6 months. Five patients were advised to stop
their medication at the 3–6 months evaluation, because
of limited benefit and or potential aggravation of other
symptoms and side effects, such as effects on mood, be-
havior or constipation.
Discussion
To our knowledge, this is the first study describing the ex-
perience with a multidisciplinary team approach towards
children and adults with YMDs. Based on the results it is
likely that patients with YMDs benefit from a multidiscip-
linary team strategy with regard to MD classification, diag-
nostic yield and targeted treatment strategies.
The multifaceted nature of YMDs served as an im-
pulse for setting up our multidisciplinary outpatient
clinic, because the complexity of YMDs often leads to a
time-consuming and burdensome diagnostic process [1,
6, 7]. This issue is reflected by a mean symptom dur-
ation of 74% of our patients’ life spans, which is in line
with the results of a previous study [7]. In 58% of the pa-
tients, the team revised the MD classification or defined
another MD as the most prominent clinical symptom.
We think this high percentage of revisions may be due
to the combined expertise of a pediatric neurologist,
trained to distinguish normal developmental from ab-
normal movements, and a movement disorder specialist,
trained to establish the phenomenology of clinical MD
syndromes [1, 8]. Although we are aware that there is no
gold standard for clinical MD classification, additional
investigations such as EEG/EMG for myoclonus con-
firmed the clinical diagnosis in 24/29 of our cases [22].
The presence of non-neurological features in 39% of our
YMD cohort underscores the complexity of the clinical
presentations in a significant part of this population, and
the combined expertise of a pediatrician and a clinical
geneticist to include all symptoms, facilitated the diag-
nostic process.
The team identified a etiological diagnosis in 24/71
(34%) previously undiagnosed patients, of which 17 were
found to have monogenetic disorders. In contrast, in a
study with 260 patients non-tic YMDs patients, who
were referred to a neurologist specialized in YMDs be-
tween 2004 and 2013, a definitive genetic diagnosis was
made in 17%. [7]. We realize that the genetic advances
of the past decade are likely to have contributed to the
higher yield in our sample, however we hypothesize that
















Cessation of drug 1 1
Botulinum toxin 5 5
Deep brain stimulation 5 4
Paramedical 2 2
Total dystonia 27 20
Myoclonus
Pharmacological Clonazepam 10 10
Ketogenic diet 4 1
Paramedical 4 2





Cessation of drug 4 2
Botulinum toxin 1 1
Paramedical 3 2




Pharmacological L-dopa 2 1
Total 60 43
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the team’s broad and combined expertise has also been
an important contributing factor. Furthermore, the diag-
nostic yield was obtained in a relatively short period of
time, as a multidisciplinary team strategy facilitates im-
mediate decision-making in comparison to the normal
serial process involving multiple referrals, therefore min-
imizing the burden for the patients and their families.
After critical appraisal of phenotype and etiology,
therapeutic strategies were considered and tailored to in-
dividual patient needs. The team gave specific advice on
treatment for 60% of patients, with 72% (n = 42) of them
or their caregivers reporting a subjective positive effect
of the suggested treatment on follow-up. The effective-
ness of treatment was only assessed through a semi-
structured questionnaire and it was therefore not
possible to draw more detailed conclusions on objective
and/or long-term outcome measures of its effectiveness.
Nevertheless, the large number of patients in which
treatment was initiated at our clinic may reflect a poten-
tial under-treatment of YMDs, likely to significantly im-
pact the patient’s quality of life. The low number of
patients that were already treated for their MD is re-
markable, in particular when taking into account that
the mean MD severity of these 60 cases was significant
(5 on a scale of 7). Low treatment rates and potential
under-treatment have also been reported in MDs in chil-
dren with inborn errors of metabolism, [13] despite the
fact that it has been shown that symptomatic treatment
may significantly improve patients’ daily functioning and
quality of life [14, 23, 24].
The results of this exploratory study indicate that
YMDs patients might benefit from a multidisciplinary
team approach in terms of diagnosis and treatment in
comparison to the referring specialists. However, inter-
pretation of the results is limited by the lack of a control
group of patients’ receiving assessment by a pediatric
movement disorder specialist, or in comparison to as-
sessments by an alternative team consisting of two or
three specialists. Inclusion of such a control group was
not feasible in our center. Nevertheless, we think that
this single-institution experience indicates that a dedi-
cated multidisciplinary approach to YMDs disorders
may facilitate phenotyping and improve recognition of
rare disorders.
Notably, in this study, the age at presentation at our
outpatient clinic ranged from 1 to 33 years, which is
beyond the standard upper limit of 18 years for
pediatric care. Distinguishing early-onset from later-
onset MDs is useful for diagnostic purposes [3, 4].
However, we believe that the age of symptom-onset in
these patients is a more important inclusion criterion
than the age at time of referral, especially because long
delays between symptom-onset and diagnosis have been
reported. [7] Therefore, we propose to consider patients
with YMDs as a spectrum, irrespective of the age of
referral, and to allow all complex YMD patients to
benefit from the combined expertise of a multidiscip-
linary team, crossing barriers between pediatric and
adult neurology.
Conclusion
In summary, our results suggest that a multidisciplinary
approach might help tackle the complexity of diagnosis
and managing complex YMDs. Our experience indicates
that this approach may improve recognition of rare dis-
orders, with a good diagnostic yield and a minimal diag-
nostic delay. Future studies are needed to investigate the
cost-benefit ratio of a multidisciplinary approach in
comparison to regular subspecialty care, preferably using
a prospective study design with standardized clinical as-
sessments to systematically evaluate treatment effects.
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EEG/EMG: Electroencephalography/electromyography; MD: Movement disorder;
YMD: Young-onset movement disorder
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